Expression of Concern - PubMed
Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
An official website of the United States government
Here's how you know
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
The site is secure.
The
https://
ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
Log in
Show account info
Close
Account
Logged in as:
username
Dashboard
Publications
Account settings
Log out
Access keys
NCBI Homepage
MyNCBI Homepage
Main Content
Main Navigation
Search:
Search
Advanced
Clipboard
User Guide
Save
Email
Send to
Clipboard
My Bibliography
Collections
Citation manager
Display options
Display options
Format
Abstract
PubMed
PMID
Save citation to file
Format:
Summary (text)
PubMed
PMID
Abstract (text)
CSV
Create file
Cancel
Email citation
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
To:
Subject:
Body:
Format:
Summary
Summary (text)
Abstract
Abstract (text)
MeSH and other data
Send email
Cancel
Add to Collections
Create a new collection
Add to an existing collection
Name your collection:
Name must be less than 100 characters
Choose a collection:
Unable to load your collection due to an error
Please try again
Add
Cancel
Add to My Bibliography
My Bibliography
Unable to load your delegates due to an error
Please try again
Add
Cancel
Your saved search
Name of saved search:
Search terms:
Test search terms
Would you like email updates of new search results?
Saved Search Alert Radio Buttons
Yes
No
Email:
(
change
)
Frequency:
Monthly
Weekly
Daily
Which day?
The first Sunday
The first Monday
The first Tuesday
The first Wednesday
The first Thursday
The first Friday
The first Saturday
The first day
The first weekday
Which day?
Sunday
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Report format:
Summary
Summary (text)
Abstract
Abstract (text)
PubMed
Send at most:
1 item
5 items
10 items
20 items
50 items
100 items
200 items
Send even when there aren't any new results
Optional text in email:
Save
Cancel
Create a file for external citation management software
Create file
Cancel
Your RSS Feed
Name of RSS Feed:
Number of items displayed:
5
10
15
20
50
100
Create RSS
Cancel
RSS Link
Copy
Full text links
HighWire
Full text links
Actions
Cite
Collections
Add to Collections
Create a new collection
Add to an existing collection
Name your collection:
Name must be less than 100 characters
Choose a collection:
Unable to load your collection due to an error
Please try again
Add
Cancel
Permalink
Permalink
Copy
Display options
Display options
Format
Abstract
PubMed
PMID
Page navigation
Title & authors
Abstract
Expression of concern for
Publication types
LinkOut - more resources
Title & authors
Abstract
Expression of concern for
Publication types
LinkOut - more resources
Anticancer Res
Actions
Search in PubMed
Search in NLM Catalog
Add to Search
.
2026 Jun 9;46(6):e3243.
doi: 10.21873/anticanres.18276.
Expression of Concern
No authors listed
PMID:
42300708
DOI:
10.21873/anticanres.18276
Item in Clipboard
Expression of Concern
No authors listed.
Anticancer Res
.
2026
.
Show details
Display options
Display options
Format
Abstract
PubMed
PMID
Anticancer Res
Actions
Search in PubMed
Search in NLM Catalog
Add to Search
.
2026 Jun 9;46(6):e3243.
doi: 10.21873/anticanres.18276.
PMID:
42300708
DOI:
10.21873/anticanres.18276
Item in Clipboard
Full text links
Cite
Display options
Display options
Format
Abstract
PubMed
PMID
Abstract
Regarding: Hulscher et al., “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” Anticancer Research Vol. 46, No. 6, pp. 3243-3255, 2026. The Editorial Board of Anticancer Research is issuing an official Expression of Concern regarding the article cited above. The study was published purely as “hypothesis-generating", opening the discussion for repurposing of these substances, establishing the ground for future approved, randomized clinical trials. Following publication, serious scientific concerns were raised by the international medical community regarding the verifiability and statistical reliability, and ethical oversight of the underlying dataset. In formal correspondence to the journal dated June 4, 2026, the authors clarified that the study cohort was not drawn from an unverified consumer survey, but instead comprised “provider-screened cancer patients enrolled in a structured prospective cohort” managed via an internal clinical workflow and licensed provider consultations. While the Editorial Board acknowledges the authors' transparency regarding the text-level limitations of selfreported data, a study published in a peer-reviewed oncology journal that reports a “Clinical Benefit Ratio of 84.4%” and specific percentages of “tumor regression” must rest on a verifiably real clinical foundation and adhere to established ethical frameworks for human subject research to maintain its validity in the permanent scholarly record. Anticancer Research does not endorse or condone the unvalidated off-label use of medications for unapproved oncological indications. Disclosing limitations does not exempt a clinical dataset from the foundational scientific requirements of empirical verifiability and independent ethical oversight. Accordingly, based on the authors' confirmation of an established clinical provider-patient workflow, the journal is initiating a formal Post-Publication Data Integrity and Ethical Oversight Audit. This investigation will evaluate the mandatory Institutional Review Board (IRB) approval or exemption documentation, the de-identified, source-verified clinical records confirming the baseline cancer diagnoses of the 197 initial participants and the objective medical documentation supporting the reported anatomical regressions. This Expression of Concern will remain prominently appended to the publication record online and in all indexing databases while this formal data and ethical verification audit is underway.
PubMed Disclaimer
Expression of concern for
Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.
Hulscher N, Victory K, Thorp JA, Pinsky D, Diaz-Villalobos A, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, McCULLOUGH PA, Risch H.
Hulscher N, et al.
Anticancer Res. 2026 Jun;46(6):3243-3255. doi: 10.21873/anticanres.18194.
Anticancer Res. 2026.
PMID:
42203321
Publication types
Expression of Concern
Actions
Search in PubMed
Search in MeSH
Add to Search
LinkOut - more resources
Full Text Sources
HighWire
Miscellaneous
NCI CPTAC Assay Portal
Full text links
[x]
HighWire
[x]
Cite
Copy
Download .nbib
.nbib
Format:
AMA
APA
MLA
NLM
Send To
Clipboard
Email
Save
My Bibliography
Collections
Citation Manager
[x]
NCBI Literature Resources
MeSH
PMC
Bookshelf
Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Follow NCBI
Twitter
Facebook
LinkedIn
GitHub
Connect with NLM
Twitter
SM-Facebook
SM-Youtube
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
Web Policies
FOIA
HHS Vulnerability Disclosure
Help
Accessibility
Careers
NLM
NIH
HHS
USA.gov